Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.

NCT00662155 · ClinicalTrials.gov registry record · NA

The Role of Partial Reinforcement in the Long Term Management of Insomnia

A NA study of Primary Insomnia, sponsored by University of Pennsylvania.

Completed
Registry status
NA
Development phase
129
Enrollment target
1
Study location

NCT00662155: Completed NA study of Primary Insomnia, sponsored by University of Pennsylvania.

NCT00662155 is a NA study of Primary Insomnia that has completed, run by University of Pennsylvania. The registered enrollment target is 129 participants, above the 115-participant average among 12 other Primary Insomnia trials with a reported enrollment target (12% higher). The trial reports 1 study location across 1 state. According to ClinicalTrials.gov, the official US trial registry.

View on ClinicalTrials.gov ↗

View your shortlist →

The verdict

NCT00662155, a NA study of Primary Insomnia, has completed, sponsored by University of Pennsylvania.

COMPLETED
Registry status
NA
Development phase
129 participants
Enrollment target
1
Study location

Study Summary

The lack of scientific attention devoted to the placebo effect as a phenomenon in its own right probably reflects the paucity of theoretical positions within which to organize the existing data and design new research. The proposed investigation 1) is an attempt to advance from a descriptive to an experimental analysis of the placebo effect, taking into account classical conditioning effects, and 2) examines the clinical implications of partial reinforcement as it is applied to the treatment of insomnia. Subjects with primary insomnia will be treated with zolpidem for a period of one month and then randomized to one of four groups for a period of 12 weeks: one receiving full dose zolpidem on a nightly basis (continuous reinforcement), one receiving full dose zolpidem on 14 of 28 nights where placebo is provided on non-drug nights (partial reinforcement), one receiving full dose zolpidem on 14 of 28 nights where no pills are imbibed on non-drug nights (intermittent dosing), and one receiving 5 mg dose zolpidem on a nightly basis (continuous reinforcement with half the standard dose). Following treatment, subjects will be entered into an extinction protocol during which they will 1) continue on the schedule assigned during the experimental period, 2) receive only placebo, or 3) receive neither drug nor placebo. Sleep and daily functioning will be monitored on a daily basis via sleep diaries for the duration of the study. It is hypothesized that, holding cumulative dose constant, a partial schedule of reinforcement will enable patients to better maintain their clinical gains as compared to subjects that receive either continuous reinforcement with half the standard dose or half the frequency of use. Relevance: The proposed research is not an attempt to offer a behavioral alternative to drug treatment; it is an attempt to acknowledge and capitalize on a behavioral dimension in the design of drug treatment protocols. The value of the proposed research resides in its cap

Primary Outcome

The standard measure for clinical trials research in insomnia is the sleep diary. This prospective self-report measurement tool provides an assessment of sleep continuity as a function of treatment.

Conditions Studied

Interventions

  • DRUG Placebos
  • DRUG Zolpidem

Study Locations (1)

Pennsylvania

  • University of Pennsylvania - Philadelphia

Trial Details

FieldValue
Enrollment Target 129 participants
Start Date 2006-07
Est. Completion 2013-06
Phase NA
University of Pennsylvania

1,423 total trials

What the finished NCT00662155 record still lists

NCT00662155 is an interventional study that assigns participants to a tested intervention. The registered 129 participants enrollment target is mid-sized for trials with a published cap, above the 115-participant average among 12 other Primary Insomnia trials with a reported enrollment target (12% higher).

The record links to 1 condition, with Primary Insomnia appearing as the primary indexed condition, and to 2 interventions - of which Placebos is the first listed.

NCT00662155 reports a single indexed study location in Pennsylvania.

Frequently Asked Questions

What is clinical trial NCT00662155 about?

NCT00662155 is a clinical study titled "The Role of Partial Reinforcement in the Long Term Management of Insomnia". The lack of scientific attention devoted to the placebo effect as a phenomenon in its own right probably reflects the paucity of theoretical positions within which to organize the existing data and design new research. The proposed investigation 1) is an attempt to advance from a descriptive to an e...

What is the current status of trial NCT00662155?

This trial is currently completed. It is a NA study. The enrollment target is 129 participants. The study started on 2006-07. Estimated completion is 2013-06.

What conditions does trial NCT00662155 study?

This clinical trial studies the following conditions: Primary Insomnia.

What interventions are being tested in trial NCT00662155?

The interventions under investigation include: Placebos (DRUG), Zolpidem (DRUG).

Who is sponsoring clinical trial NCT00662155?

This trial is sponsored by University of Pennsylvania, which has 1,423 total clinical trials registered on ClinicalTrials.gov.

Where is trial NCT00662155 being conducted?

This trial has 1 study location across Pennsylvania. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.

Similar trials for Primary Insomnia

Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.

Where NCT00662155's enrollment target sits among peer trials

129 3rd of 12 higher than 10 of 12 other Primary Insomnia trials

participants (enrollment target), bucketed by value

Each bar is a band; taller bars hold more other Primary Insomnia trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.

Source ClinicalTrials.gov registry export · 2026-08-08

Nationwide trials with similar profiles

Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.

Similar enrollment target

  • NCT03619850 · 129 participants · Phase 3

    A Study to Evaluate the Safety (Compared to Iron Sucrose), Efficacy and Pharmacokinetics of Ferumoxytol for the Treatment of Iron Deficiency Anemia (IDA) in Pediatric Subjects With Chronic Kidney Disease (CKD)

  • NCT05704361 · 129 participants · Phase 1

    A Study to Investigate the Safety, Tolerability, and Processing by the Body of Intravenous and Subcutaneous RO7121932 Administration in Participants With Multiple Sclerosis

  • NCT05919849 · 129 participants · Phase 1

    Supporting Parents in Affirming Their Children's Experiences of Stigma

  • NCT06313749 · 129 participants · NA

    Safety and Effectiveness of Minimally Invasive Micro Sclerostomy (MIMS®) to Reduce Intraocular Pressure in Open-Angle Glaucoma Which is Not Controlled Despite Polypharmacy

Similar registry start date

  • NCT05988463 · started 2027-01-01 · Phase 1

    Dose-Escalation Study of Artesunate Patients With IPF

  • NCT07219706 · started 2026-12-10 · NA

    Dietary Fiber and Time Restricted Eating

  • NCT02831335 · started 2026-12-01

    Technical Development of Multi-Parametric Renocerebral MRI

  • NCT05962346 · started 2026-12 · NA

    Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia

Source: ClinicalTrials.gov NCT00662155, the US trial registry maintained by the National Library of Medicine. NCT00662155 (mid enrollment · single site footprint · completed) retrieved and formatted by PlainTrial, see methodology.